GABA and GLP-1 receptor agonist combination therapy modifies diabetes and Langerhans islet cytoarchitecture in a rat model of Wolfram syndrome

GABA and GLP-1 receptor agonist combination therapy modifies diabetes and Langerhans islet cytoarchitecture in a rat model of Wolfram syndrome

Abstract Background and Aim Wolfram syndrome (WS) is a rare autosomal disorder caused by WFS1 gene mutations, currently lacking approved treatments. Preclinical and clinical reports suggest that diabetes medications, such as glucagon-like peptide-1 receptor agonist (GLP1-RA), slow WS-related diabete...

Full description

Saved in:
Bibliographic Details
Main Authors: Toomas Jagomäe, Sandra Velling, Tessa Britt Tikva, Varvara Maksimtšuk, Nayana Gaur, Riin Reimets, Allen Kaasik, Eero Vasar, Mario Plaas
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Wolfram syndrome
Wfs1
GABA
GLP1-RA
Liraglutide
Langerhans islet
Online Access:https://doi.org/10.1186/s13098-025-01651-6
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items